Resources

CAR T Academy Resources

Diagnosis and management of mantle cell lymphoma: A British Society for Haematology guideline

Authors:
Toby A Eyre, Mark J Bishton, Rory McCulloch, Maeve O'Reilly, Robin Sanderson, Geetha Menon, Sunil Iyengar, David Lewis, Jonathan Lambert, Kim M Linton, Pamela McKay; Haemato-Oncology Task Force of the British Society for Haematology

02.01.2024


Journal (Date):

Br J Haematol (2024)


Abstract Excerpt:

“The objective of this guideline is to provide healthcare professionals with clear guidance on the diagnosis and management of patients with mantle cell lymphoma.”

View Document

CD19-directed CAR T cells as first salvage therapy for large B-cell lymphoma: towards a rational approach

Authors:
Peter Dreger, Paolo Corradini, John G Gribben, Bertram Glass, Mats Jerkeman, Marie Jose Kersten, Franck Morschhauser, Alberto Mussetti, Andreas Viardot, Pier Luigi Zinzani, Anna Sureda; European Society for Blood and Marrow Transplantation and the European Hematology Association Lymphoma Group

10.12.2023


Journal (Date):

Lancet Haematol (2023)


Abstract Excerpt:

"In this Review, we provide guidance for a rational management approach to the use of commercial CD19-directed CAR T cells in the second-line treatment of LBCL, addressing crucial questions regarding eligible histologies; age, comorbidity, and tumour biology restrictions; the handling of very aggressive tumour behaviour; and holding and bridging therapies."

View Document

Long-term survivorship care after CAR-T cell therapy

Authors:
Robert Puckrin, Kareem Jamani, Victor H. Jimenez-Zepeda

28.09.2023


Journal (Date):

Eur J Haematol (2023)


Abstract Excerpt:

“In this review, we provide a practical approach to the long-term survivorship care of the CAR-T cell recipient, with a focus on the optimal strategies to address the common and challenging late complications affecting this unique population.”

View Document

Immune effector cell-associated hematotoxicity (ICAHT): EHA/EBMT consensus grading and best practice recommendations

Authors:
Kai Rejeski, Marion Subklewe, Mahmoud Aljurf, Emmanuel Bachy, Adriana Balduzzi, Pere Barba, Benedetto Bruno et al.

07.09.2023


Journal (Date):

Blood (2023)


Abstract Excerpt:

“We propose ICAHT as a novel toxicity category following immune effector cell therapy, provide a framework for its grading, review literature on risk factors, and outline expert recommendations for the diagnostic work-up and short- and long-term management.”

View Document

Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma

Authors:
Claire Roddie, Lorna Neill, Wendy Osborne, Sunil Iyengar, Eleni Tholouli, David Irvine, Sridhar Chaganti, Caroline Besley, Adrian Bloor, Ceri Jones, Ben Uttenthal, Rod Johnson, Robin Sanderson, Kathleen Cheok, Maria Marzolini, William Townsend, Maeve O'Reilly, Amy A. Kirkwood, Andrea Kuhnl

27.06.2023


Journal (Date):

Blood Adv (2023)


Abstract Excerpt:

“Here, we report outcomes of bridging therapy (BT) in 375 adult patients with r/r LBCL undergoing leukapheresis for Axi-cel or Tisa-cel. The objectives of the study were to identify which patients respond to BT (including those who achieve CR to BT and proceed to CAR-T infusion), and a comparison of the impact of BT on CAR-T therapy safety and efficacy outcomes between patient groups treated with Axi-cel and Tisa-cel.”

View Document

Transplant-ineligible but chimeric antigen receptor T cells eligible: a real and relevant population

Authors:
Samuel Vic, Jean Lemoine, Philippe Armand,
François Lemonnier, Roch Houot

24.09.2022


Journal (Date):

European Journal of Cancer (2022)


Abstract Excerpt:

“As the relative role of ASCT and CAR T-cells evolves, recognizing and defining this population may be increasingly relevant. Here, we review criteria which may help identify this 'ASCT-ineligible but CAR T-cells eligible' population of patients.”

View Document

CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift?

Authors:
Jason Westin and Laurie Sehn

05.05.2022


Journal (Date):

Blood (2022)


Abstract Excerpt:

“In this review, we interpret the design and results of 3 randomized phase 3 trials comparing CAR T-cell therapy and ASCT and their implications for CAR T-cell therapy as a potential new standard of care for second-line treatment in appropriate patients with refractory or early relapsing LBCL.”

View Document

CAR T therapy learning resources for patients from Princess Margaret

Authors:
Princess Margaret Cancer Classes
About:

Online learning modules on CAR T therapy developed by Princess Margaret Cancer Centre for patients, caregivers, and family. These modules were co-created by patients and healthcare providers. Module topics include:
• Learn about CAR T-cell therapy
• Prepare for CAR T-cell therapy
• What to expect during T-cell collection
• Finalizing the CAR T-cell therapy plan
• What to expect during CAR T-cell therapy
• Follow-up after CAR T-cell therapy
• Learn about the role of caregivers
• Take care of your emotions

View Document

Let’s Chat CAR T (patient and caregiver resource on CAR T-cell therapy)

Authors:
Gilead/Kite
About:

letschatcart.ca provides patients and caregivers with clear, concise, practical information about CAR T, including:
• What CAR T is and how it works
• Preparing for CAR T
• Resources for finding additional information
• Helpful videos

View Document